Luke Anthony Wittenburg, BS; DVM; PhD

Assistant Professor

  • 269 Citations
  • 7 h-Index
20102019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Luke Anthony Wittenburg is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 269 Citations
  • 7 h-Index
  • 29 Article
  • 1 Review article

Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers

Wittenburg, L. A., Weishaar, K., Ramirez, D. & Gustafson, D. L., Jan 1 2019, In : Veterinary and Comparative Oncology.

Research output: Contribution to journalArticle

  • 2 Scopus citations

    Pilot study comparing serum chemotherapy levels after intra-arterial and intravenous administration in dogs with naturally occurring urinary tract tumors

    Kirsch, M., Weisse, C., Berent, A., Clifford, C., Leibman, N., Wittenburg, L. A., Solomon, S. B. & Lamb, K., Jul 1 2019, In : Canadian Journal of Veterinary Research. 83, 3, p. 187-196 10 p.

    Research output: Contribution to journalArticle

  • Simultaneous absolute quantitation of ATP-binding cassette transporters in normal dog tissues by signature peptide analysis using a LC/MS/MS method

    Wittenburg, L. A., Ramirez, D., Conger, H. & Gustafson, D. L., Feb 1 2019, In : Research in Veterinary Science. 122, p. 93-101 9 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma

    Alegre, F., Ormonde, A. R., Godinez, D. R., Illendula, A., Bushweller, J. H. & Wittenburg, L. A., Jan 1 2019, (Accepted/In press) In : Veterinary and Comparative Oncology.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma

    Alegre, F., Ormonde, A. R., Snider, K. M., Woolard, K. D., Yu, A. & Wittenburg, L. A., Dec 1 2018, In : PloS one. 13, 12, e0209941.

    Research output: Contribution to journalArticle

    Open Access
  • 5 Scopus citations